enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Monoclonal antibody therapy - Wikipedia

    en.wikipedia.org/wiki/Monoclonal_antibody_therapy

    The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly.

  3. Denosumab - Wikipedia

    en.wikipedia.org/wiki/Denosumab

    Denosumab, sold under the brand names Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [11] [12] The most common side effects are joint and muscle pain in the arms or legs. [13]

  4. Pertuzumab - Wikipedia

    en.wikipedia.org/wiki/Pertuzumab

    Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...

  5. Monoclonal antibody infusions? They're keeping many ... - AOL

    www.aol.com/news/monoclonal-antibody-infusions...

    For premium support please call: 800-290-4726 more ways to reach us

  6. Tildrakizumab - Wikipedia

    en.wikipedia.org/wiki/Tildrakizumab

    Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. [4] It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.

  7. Atoltivimab/maftivimab/odesivimab - Wikipedia

    en.wikipedia.org/wiki/Atoltivimab/maftivimab/...

    The trial enrolled pediatric and adult participants (including pregnant women) with Zaire ebolavirus infection. [3] All participants received standard, supportive care for the disease. [3] The participants and the health care providers knew which treatment was being given. [3] The primary efficacy endpoint was 28-day mortality. [2]

  8. Monoclonal antibody treatment by Eli Lilly found to cut risk ...

    www.aol.com/news/monoclonal-antibody-treatment...

    A study of nursing home residents found the monoclonal antibody treatment bamlanivimab cut the risk of COVID-19 by up to 80%, maker Eli Lilly announced.

  9. Eculizumab - Wikipedia

    en.wikipedia.org/wiki/Eculizumab

    Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica.